《新股消息》再鼎醫藥 (09688.HK):未有扭虧時間表 兩產品註冊待審批
再鼎醫藥(09688.HK)首席財務官曹基哲表示,公司目前雖仍然錄得虧損,亦未有扭虧時間表,但強調除已商業化的Zejula及Optune外,產品線中有14個項目處於臨床階段,涵蓋腫瘤、抗感染及自體免疫性疾病領域,當中2個項目已提交中國新藥註冊申請,待通過審批後可開始銷售。
他透露,來港上市主要是由於見到不少發展機會,期望籌集資金推動公司增長,同時認為香港金融市場對發展中的創新公司友好,亦可更接近亞太區投資者,未來會繼續借助兩地上市地位,接觸全球資本市場。
集資所得約25%預期將用於探索新的全球授權及合作機會,他表示疫情限制出行,對尋找新機會有影響,將加強內部研發能力,並會與其他藥企合作增強產品線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.